175137-38-9

Basic information

• Product Name: ETHYL 2-(4-FLUOROPHENYL)-3-(TRIFLUOROMETHYL)PYRAZOLE-4-CARBOXYLATE
• Synonyms: ETHYL 2-(4-FLUOROPHENYL)-3-(TRIFLUOROMETHYL)PYRAZOLE-4-CARBOXYLATE;ETHYL 5-(TRIFLUOROMETHYL)-1-(4-FLUOROPHENYL)-1H-PYRAZOLE-4-CARBOXYLATE;BUTTPARK 85\18-100;Ethyl 2-(4-fluorophenyl)-3-(trifluoromethyl)pyrazole-4-carboxylate 95%;Ethyl2-(4-fluorophenyl)-3-(trifluoromethyl)pyrazole-4-carboxylate95%;Ethyl2-(4-Fluorophenyl)-3-(;Ethyl 1-(4-fluorophenyl)-5-(trifluoroMethyl)-1H-pyrazole-4-carboxylate
• CAS NO: 175137-38-9
• Molecular Formula: C₁₃H₁₀F₄N₂O₂
• Molecular Weight: 302.22
• Mol File: 175137-38-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 140 °C
• Flash Point: 166 °C
• Appearance: /
• Density: 1.37 g/cm³
• Vapor Pressure: 1.04E-07mmHg at 25°C
• Refractive Index: 1.651
• PKA: -5.93±0.10(Predicted)
• CAS DataBase Reference: ETHYL 2-(4-FLUOROPHENYL)-3-(TRIFLUOROMETHYL)PYRAZOLE-4-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-(4-FLUOROPHENYL)-3-(TRIFLUOROMETHYL)PYRAZOLE-4-CARBOXYLATE(175137-38-9)
• EPA Substance Registry System: ETHYL 2-(4-FLUOROPHENYL)-3-(TRIFLUOROMETHYL)PYRAZOLE-4-CARBOXYLATE(175137-38-9)

Safety Data

• Hazard Codes: Xi
• WGK Germany: 3
• Hazardous Substances Data: 175137-38-9(Hazardous Substances Data)

Usage

Description

Ethyl 2-(4-fluorophenyl)-3-(trifluoromethyl)pyrazole-4-carboxylate is a chemical compound that serves as an intermediate in the synthesis of pyrazolylisoxazoles, which are known to have potential applications in the pharmaceutical industry.

Uses

Used in Pharmaceutical Industry:
Ethyl 2-(4-fluorophenyl)-3-(trifluoromethyl)pyrazole-4-carboxylate is used as a chemical intermediate for the preparation of pyrazolylisoxazoles, which are compounds with potential applications in the development of drugs targeting IL-17, a protein involved in the immune system and associated with various inflammatory and autoimmune diseases.
As an intermediate in the synthesis of pyrazolylisoxazoles, Ethyl 2-(4-fluorophenyl)-3-(trifluoromethyl)pyrazole-4-carboxylate plays a crucial role in the development of new therapeutic agents that can potentially modulate the activity of IL-17, offering novel treatment options for patients suffering from conditions such as psoriasis, rheumatoid arthritis, and multiple sclerosis.

InChI:InChI=1/C11H7FN2S/c12-8-3-1-7(2-4-8)10-5-9(14)11(6-13)15-10/h1-5H,14H2

Upstream product

• 571-55-1 ethyl 2-(ethoxymethylidene)-4,4,4-trifluoro-3-oxobutanoate 
• 823-85-8 4-fluorophenyhydrazine hydrochloride 
• 267243-86-7 2-dimethylaminomethylidene-4,4,4-trifluoro-3-oxobutyrate ethyl ester 
• 371-14-2 4-fluorophenylhydrazine 
• 372-31-6 ethyl 4,4,4-trifluoroacetoacetate 
• 100-63-0 phenylhydrazine 

Downstream Products

• 1391943-57-9 3-(2-chloro-6-fluorophenyl)-5-(1-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)isoxazole 
• 618070-62-5 1-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid 
• 1082827-27-7 [1-(4-fluorophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]acetic acid 

Relevant articles and documents

Method for synthesizing 1-substituted phenyl-5-trifluoromethyl (difluoromethyl)-4-pyrazole carboxylic acid

The invention relates to a method for synthesizing 1-substituted phenyl-5-trifluoromethyl (difluoromethyl)-4-pyrazole carboxylic acid. The method is as follows: performing a ring-forming reaction of phenylhydrazine or substituted phenylhydrazine with inte

IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION

The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.